Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni
Isaac
I
Assaf Harofe Medical Center, Zeriffin, Beer Yaakov, Israel.
Garzozi
Hanna J
HJ
Barequet
Irina S
IS
Segev
Fanni
F
Varssano
David
D
Sartani
Gil
G
Chetrit
Noa
N
Bakshi
Erez
E
Zadok
David
D
Tomkins
Oren
O
Litvin
Gilad
G
Jacobson
Kenneth A
KA
Fishman
Sari
S
Harpaz
Zivit
Z
Farbstein
Motti
M
Yehuda
Sara Bar
SB
Silverman
Michael H
MH
Kerns
William D
WD
Bristol
David R
DR
Cohn
Ilan
I
Fishman
Pnina
P
D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D058909:Adenosine A3 Receptor Agonists; D000284:Administration, Oral; D003315:Cornea / Q000378:metabolism; D004311:Double-Blind Method; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D015590:Fluorophotometry; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D013666:Tears / Q000502:physiology; D016896:Treatment Outcome
D058909:Adenosine A3 Receptor Agonists; C478920:CF101; D000241:Adenosine